{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:47:54Z","timestamp":1778946474435,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T00:00:00Z","timestamp":1479686400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s00535-016-1285-y","type":"journal-article","created":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T06:37:00Z","timestamp":1479710220000},"page":"520-533","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II\/III study"],"prefix":"10.1007","volume":"52","author":[{"given":"Hiromitsu","family":"Kumada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyasu","family":"Karino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Chayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norifumi","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Okanoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshito","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Mochida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Yoshiji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Takaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyoshi","family":"Yatsuzuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsuo","family":"Yodoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Iwasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael N.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Black","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luzelena","family":"Caro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice","family":"Wahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,21]]},"reference":[{"issue":"Suppl 1","key":"1285_CR1","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","volume":"61","author":"E Gower","year":"2014","unstructured":"Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(Suppl 1):S45\u201357.","journal-title":"J Hepatol"},{"issue":"2","key":"1285_CR2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1469-0691.2010.03432.x","volume":"17","author":"D Lavanchy","year":"2011","unstructured":"Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17(2):107\u201315.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"1285_CR3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000252782","volume":"53","author":"H Chung","year":"2010","unstructured":"Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50\u00a0years in Japan. Intervirology. 2010;53(1):39\u201343.","journal-title":"Intervirology"},{"issue":"Suppl 1","key":"1285_CR4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000048270","volume":"62","author":"H Yoshizawa","year":"2002","unstructured":"Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology. 2002;62(Suppl 1):8\u201317.","journal-title":"Oncology"},{"issue":"2","key":"1285_CR5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/hepr.12645","volume":"46","author":"Y Asahina","year":"2016","unstructured":"Asahina Y, Izumi N, Hiromitsu K, et al. JSH guidelines for the management of hepatitis C virus infection: a 2016 update for genotype 1 and 2. Hepatol Res. 2016;46(2):129\u201365.","journal-title":"Hepatol Res"},{"key":"1285_CR6","unstructured":"Zepatier (elbasvir and grazoprevir) package insert. Whitehouse Station: Merck; 2016."},{"issue":"8","key":"1285_CR7","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1128\/AAC.00324-12","volume":"56","author":"V Summa","year":"2012","unstructured":"Summa V, Ludmerer SW, McCauley JA, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3\/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother. 2012;56(8):4161\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"1285_CR8","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/cmdc.201300343","volume":"8","author":"CA Coburn","year":"2013","unstructured":"Coburn CA, Meinke PT, Chang W, et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem. 2013;8(12):1930\u201340.","journal-title":"ChemMedChem"},{"issue":"9973","key":"1285_CR9","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(14)61795-5","volume":"385","author":"E Lawitz","year":"2015","unstructured":"Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12\u00a0weeks versus 18\u00a0weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1075\u201386.","journal-title":"Lancet"},{"issue":"9973","key":"1285_CR10","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(14)61793-1","volume":"385","author":"M Sulkowski","year":"2015","unstructured":"Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8\u00a0weeks versus 12\u00a0weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV\/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1087\u201397.","journal-title":"Lancet"},{"issue":"1","key":"1285_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","volume":"163","author":"S Zeuzem","year":"2015","unstructured":"Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir\u2013elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163(1):1\u201313.","journal-title":"Ann Intern Med"},{"issue":"3","key":"1285_CR12","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jhep.2015.04.009","volume":"63","author":"X Forns","year":"2015","unstructured":"Forns X, Gordon SC, Zuckerman E, et al. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol. 2015;63(3):564\u201372.","journal-title":"J Hepatol"},{"issue":"1","key":"1285_CR13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/cid\/civ722","volume":"62","author":"M Buti","year":"2016","unstructured":"Buti M, Gordon SC, Zuckerman E, et al. Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE. Clin Infect Dis. 2016;62(1):32\u20136.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"1285_CR14","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1016\/S2352-3018(15)00114-9","volume":"2","author":"JK Rockstroh","year":"2015","unstructured":"Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2(8):e319\u201327.","journal-title":"Lancet HIV"},{"issue":"10003","key":"1285_CR15","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","volume":"386","author":"D Roth","year":"2015","unstructured":"Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386(10003):1537\u201345.","journal-title":"Lancet"},{"issue":"2","key":"1285_CR16","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1053\/j.gastro.2014.04.006","volume":"147","author":"MP Manns","year":"2014","unstructured":"Manns MP, Vierling JM, Bacon BR, et al. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterology. 2014;147(2):366\u201376.","journal-title":"Gastroenterology"},{"issue":"6","key":"1285_CR17","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","volume":"15","author":"M Mizokami","year":"2015","unstructured":"Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12\u00a0weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015;15(6):645\u201353.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"1285_CR18","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/hep.27972","volume":"62","author":"H Kumada","year":"2015","unstructured":"Kumada H, Chayama K, Rodrigues L Jr, et al. Randomized phase 3 trial of ombitasvir\/paritaprevir\/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology. 2015;62(4):1037\u201346.","journal-title":"Hepatology"},{"issue":"1","key":"1285_CR19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00535-015-1080-1","volume":"51","author":"T Kan","year":"2016","unstructured":"Kan T, Hashimoto S, Kawabe N, et al. The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay. J Gastroenterol. 2016;51(1):63\u201370.","journal-title":"J Gastroenterol"},{"issue":"6","key":"1285_CR20","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","volume":"59","author":"H Kumada","year":"2014","unstructured":"Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59(6):2083\u201391.","journal-title":"Hepatology"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-016-1285-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-016-1285-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-016-1285-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T00:05:12Z","timestamp":1498349112000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-016-1285-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,21]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["1285"],"URL":"https:\/\/doi.org\/10.1007\/s00535-016-1285-y","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,21]]}}}